Olumiant Hepatic Dosing Recommendations
For rheumatoid arthritis and alopecia areata: no dose adjustment is needed for mild or moderate hepatic impairment (Child-Pugh A or B), but Olumiant is not recommended in severe hepatic impairment (Child-Pugh C). 1
Indication-Specific Dosing
Rheumatoid Arthritis and Alopecia Areata
- Mild hepatic impairment (Child-Pugh A): No dose adjustment required 1
- Moderate hepatic impairment (Child-Pugh B): No dose adjustment required 1
- Severe hepatic impairment (Child-Pugh C): Not recommended 1
The FDA label explicitly states that Olumiant has not been studied in patients with rheumatoid arthritis or alopecia areata and severe hepatic impairment, therefore use is not recommended in this population 1.
COVID-19
The approach differs for COVID-19 patients:
- Mild hepatic impairment (Child-Pugh A): No dose adjustment required
- Moderate hepatic impairment (Child-Pugh B): No dose adjustment required
- Severe hepatic impairment (Child-Pugh C): Use only if potential benefit outweighs potential risk 1
This represents a more permissive stance for COVID-19 given the acute, life-threatening nature of severe disease, though it remains unstudied in this population 1.
Important Monitoring Considerations
Interrupt Olumiant immediately if ALT or AST elevations occur and drug-induced liver injury (DILI) is suspected, continuing interruption until DILI is excluded 1. This applies across all indications and baseline hepatic function levels.
The consensus statement on JAK inhibitors recommends monitoring transaminases at 1 month, 3 months, and then periodically every 3 months during treatment 2. This monitoring schedule should be followed regardless of baseline hepatic function.
Clinical Context
The lack of dose adjustment recommendations for mild-to-moderate hepatic impairment aligns with baricitinib's pharmacokinetic profile. The drug is primarily renally eliminated rather than hepatically metabolized, which explains why renal function has a more significant impact on dosing than hepatic function 1. This contrasts with other JAK inhibitors like tofacitinib, which requires dose reduction to 5 mg once daily in moderate hepatic impairment (Child-Pugh B) 2.
The conservative approach for severe hepatic impairment reflects the absence of pharmacokinetic data in this population rather than documented harm, consistent with standard pharmaceutical development practices when hepatic metabolism studies are not conducted 1.